The survival rate of laryngeal squamous cell carcinoma: impact of IL1RAP rs4624606, IL1RL1 rs1041973, IL-6 rs1800795, BLK rs13277113, and TIMP3 rs9621532 single nucleotide polymorphisms.
BLK rs13277113
IL-6 rs1800795
IL1RAP rs4624606
IL1RL1 rs1041973
Laryngeal squamous cell carcinoma
TIMP3 rs9621532
Journal
Discover. Oncology
ISSN: 2730-6011
Titre abrégé: Discov Oncol
Pays: United States
ID NLM: 101775142
Informations de publication
Date de publication:
22 Jan 2023
22 Jan 2023
Historique:
received:
18
11
2022
accepted:
16
01
2023
entrez:
22
1
2023
pubmed:
23
1
2023
medline:
23
1
2023
Statut:
epublish
Résumé
Results of laryngeal squamous cell carcinoma (LSCC) treatment and the 5 year survival rate of these patients remain poor. To purify therapeutic targets, investigation of new specific and prognostic blood-based markers for LSCC development is essential. In the present study, we evaluated five single nucleotide polymorphisms (SNPs): IL1RAP rs4624606, IL1RL1 rs1041973, IL-6 rs1800795, BLK rs13277113, and TIMP3 rs9621532, and determined their associations with the patients' 5 year survival rate. Also, we performed a detailed statistical analysis of different LSCC patients' characteristics impact on their survival rate. Three hundred fifty-three LSCC patients and 538 control subjects were included in this study. The multivariable Cox regression analysis revealed a significant association between patients' survival rate and distribution of IL1RAP rs4624606 variants: patients carrying AT genotype at IL1RAP rs4624606 had a lower risk of death (p = 0.044). Also, it was revealed that tumor size (T) (p = 0.000), tumor differentiation grade (G) (p = 0.015), and IL1RAP rs4624606 genotype (p = 0.044) were effective variables in multivariable Cox regression analysis prognosing survival of LSCC patients. The specific-LSCC 5 year survival rate was 77%. In summary, our findings indicate that the genotypic distribution of IL1RAP rs4624606 influences the 5 year survival rate of LSCC patients. The results of the present study facilitate a more complete understanding of LSCC at the biological level, thus providing the base for the identification of new specific and prognostic blood-based markers for LSCC development.
Identifiants
pubmed: 36682035
doi: 10.1007/s12672-023-00619-0
pii: 10.1007/s12672-023-00619-0
pmc: PMC9867797
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8Informations de copyright
© 2023. The Author(s).
Références
Eur Arch Otorhinolaryngol. 2022 Mar;279(3):1431-1434
pubmed: 35031859
PLoS One. 2019 Nov 20;14(11):e0224665
pubmed: 31747406
Ann Diagn Pathol. 2021 Oct;54:151787
pubmed: 34242969
Ther Adv Med Oncol. 2019 Jul 16;11:1758835919864247
pubmed: 31360238
Cancers (Basel). 2020 Feb 07;12(2):
pubmed: 32046104
J Biol Chem. 1996 Mar 8;271(10):5777-83
pubmed: 8621445
Curr Opin Otolaryngol Head Neck Surg. 2003 Apr;11(2):73-7
pubmed: 14515082
Int J Immunogenet. 2012 Aug;39(4):321-7
pubmed: 22313735
JAMA Otolaryngol Head Neck Surg. 2021 Dec 1;147(12):1045-1052
pubmed: 34297790
Front Physiol. 2020 Jun 16;11:661
pubmed: 32612540
Cancer Res. 2014 May 15;74(10):2669-76
pubmed: 24675360
Gene. 2020 Jul 15;747:144700
pubmed: 32330537
Clin Cancer Res. 2016 Jul 1;22(13):3218-26
pubmed: 26839145
Ear Nose Throat J. 2022 Feb;101(2):89-94
pubmed: 32703031
Leukemia. 2014 Oct;28(10):2109-12
pubmed: 24919804
Pathol Oncol Res. 2018 Oct;24(4):937-940
pubmed: 29524167
Arthritis Rheum. 2011 Jul;63(7):2091-6
pubmed: 21480188
Tumour Biol. 2017 Jul;39(7):1010428317714196
pubmed: 28670978
Int J Cancer. 2020 Nov 15;147(10):2879-2890
pubmed: 32638385
Laryngoscope. 2022 Aug;132(8):1600-1608
pubmed: 34953151
Laryngoscope Investig Otolaryngol. 2020 Jan 27;5(1):74-81
pubmed: 32128433
Front Immunol. 2017 Apr 24;8:475
pubmed: 28484466
J Rheumatol. 2011 Sep;38(9):1866-70
pubmed: 21765104
Lancet Respir Med. 2020 May;8(5):518-526
pubmed: 32203711
Head Neck. 2019 Sep;41(9):3114-3124
pubmed: 31090975
J Family Med Prim Care. 2020 May 31;9(5):2214-2218
pubmed: 32754476
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
Hum Immunol. 2014 Aug;75(8):901-8
pubmed: 24994460
J Laryngol Otol. 2016 Jan;130(1):8-14
pubmed: 26585180
CA Cancer J Clin. 2017 Jan;67(1):31-50
pubmed: 27898173
Genomics. 2000 Aug 1;67(3):284-90
pubmed: 10936050
Oral Oncol. 2018 Jun;81:35-44
pubmed: 29884412
J Cancer. 2018 Apr 27;9(11):1896-1904
pubmed: 29896273
Technol Cancer Res Treat. 2021 Jan-Dec;20:1533033821995282
pubmed: 33602046
Front Oncol. 2020 Mar 20;10:85
pubmed: 32266126
Tumour Biol. 2016 Jul;37(7):8857-67
pubmed: 26749283
Nat Immunol. 2015 May;16(5):448-57
pubmed: 25898198
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Curr Mol Med. 2018 Mar 9;17(7):471-477
pubmed: 29424312
Laryngoscope. 2020 Mar;130(3):E108-E115
pubmed: 31090946
PLoS Genet. 2011 Mar;7(3):e1001333
pubmed: 21437268
Am J Otolaryngol. 2019 Mar - Apr;40(2):213-217
pubmed: 30553600
J Natl Compr Canc Netw. 2020 Jul;18(7):873-898
pubmed: 32634781
Front Surg. 2021 Sep 24;8:717084
pubmed: 34631779
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221133690
pubmed: 36259221
Acta Otorhinolaryngol Ital. 2017 Dec;37(6):458-466
pubmed: 28663597